What is Adalimumab?
Category: Prescription Drugs
Most popular types: Humira Humira Pen Humira Pen Crohn's Disease Starter Package Show all
Adalimumab is an injectable product that can be used to treat a variety of autoimmune conditions including: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Rheumatoid arthritis | 4022 | 212 | |
| Crohn's disease | 1692 | 113 | |
| Psoriasis | 455 | 52 | |
| Ankylosing spondylitis | 331 | 51 | |
| Ulcerative colitis | 165 | 20 | |
| Psoriatic arthritis | 93 | 58 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 60 | |
| Moderate | 81 | |
| Mild | 110 | |
| None | 213 |
Commonly reported side effects and conditions associated with Adalimumab
| Side effect | Patients | Percentage |
|---|---|---|
| Headaches | 18 | |
| Fatigue | 16 | |
| Nausea | 16 | |
| Weakened immune system | 15 | |
| Injection site pain | 11 | |
| Injection site itching | 9 |
Why patients stopped taking Adalimumab
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Did not seem to work | 183 | |
| Side effects too severe | 97 | |
| Doctor's advice | 83 | |
| Other | 41 | |
| Expense | 16 | |
| Change in health plan coverage | 12 | |
| Personal research | 8 | |
| Course of treatment ended | 7 |
Duration
Stopped taking Adalimumab
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 56 | |
| 1 - 6 months | 67 | |
| 6 months - 1 year | 73 | |
| 1 - 2 years | 45 | |
| 2 - 5 years | 49 | |
| 5 - 10 years | 12 | |
| 10 years or more | 7 |
What people switch to and from
Patients started taking Adalimumab after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Etanercept (Enbrel) | 58 | |
| Infliximab (Remicade) | 46 | |
| Methotrexate (Apo-Methotrexate) | 41 | |
| Sulfasalazine (Salazopyrin) | 11 | |
| Azathioprine (Imuran) | 10 |
Patients stopped taking Adalimumab and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Etanercept (Enbrel) | 41 | |
| Infliximab (Remicade) | 24 | |
| Certolizumab (Cimzia) | 22 | |
| Abatacept (Orencia) | 18 | |
| Tofacitinib (Xeljanz) | 13 |
Last updated: